Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
CGP 37157 (HB1132)
Description:Potent, selective mitochondria Na+ / Ca2+ exchange inhibitor
Purity:>99%
Citrinin (HB3839)
Description:Mitochondrial permeability transition pore (MPTP) activator
Purity:>97%
Cyclosporin A (HB0220)
Description:Potent calcineurin inhibitor. Inhibits MPTP opening.
Purity:>99%
Disulfiram (HB1119)
Description:Reversibly stimulates SERCA Ca2+-ATPase. V-ATPase inhibitor.
Purity:>97%